Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Experts: Journavx a prescription to stem Long Island's addiction crisis
Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...
BioSpace3d
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
CenExel Celebrates FDA Approval of JOURNAVX(TM), a Groundbreaking Non-Opioid Pain Treatment
SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...
infectiousdiseaseadvisor.com6d
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval
The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.
clinicaladvisor.com6d
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval
The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to ...
How the brain can miraculously switch off pain
In the second world war, the physician Henry Beecher observed that some of his soldier patients, despite being injured on the ...
Gulf Shores pharmacist sees promise in FDA-approved nonaddictive pain medicine Journavx
For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...
fingerlakes12d
FDA approves first new non-opioid painkiller in 20 years
The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...
Yale Daily News4d
First FDA-approved non-addictive painkiller has Yale roots
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
Miami Herald4d
CenExel Celebrates FDA Approval of JOURNAVX(TM), a Groundbreaking Non-Opioid Pain Treatment
Clinical trials for JOURNAVX were conducted at four CenExel Centers of Excellence in Salt Lake City, UT; Tampa, FL; Anaheim, CA; and Atlanta, GA. These sites provided critical data that ...